Skip to main content
Figure 4 | Molecular Cancer

Figure 4

From: Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway

Figure 4

Expression analyses of prolactin receptor in tumor tissue. (A) Quantitative RT-PCR revealed a 2.5-fold upregulation of prolactin receptor mRNA expression in ES + Tum-treated tumors when compared to control tumors (B) Upper side: Immunostaining for prolactin receptor in control tumors (x10) and ES + Tum-treated tumors (left x10; right x40). Lower side: Immunostaining for prolactin receptor and cleaved cytokeratin (M30) in ES + Tum-treated tumors (x40).

Back to article page

Molecular Cancer

ISSN: 1476-4598